GLPwatch
Papers (12034)
Page 37 of 201, ranked by citation count.
- Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses.
- Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
- Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
- Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.
- Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.
- Evidence that tirzepatide protects against diabetes-related cardiac damages.
- A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
- Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
- GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A.
- Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.
- Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
- Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
- Pharmacotherapy for obesity: moving towards efficacy improvement.
- Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
- Case Report: Semaglutide-associated depression: a report of two cases.
- An overview of new GLP-1 receptor agonists for type 2 diabetes.
- Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
- GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
- Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
- Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.
- Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex.
- Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
- Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.
- GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.
- Neurobehavioral effects of liraglutide and sitagliptin in experimental models.
- Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.
- Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.
- Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
- Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.
- Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.
- Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.
- GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.
- Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
- Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
- GLP-1-based therapies: the dilemma of uncertainty.
- Practical Use of Pharmacotherapy for Obesity.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
- Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
- Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method.
- Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
- Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus.
- Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.
- Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis.
- Incretin agents in type 2 diabetes.
- Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
- Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
- Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.
- Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
- No benefit of additional treatment with exenatide in patients with an acute myocardial infarction.
- Liraglutide in clinical practice: dosing, safety and efficacy.
- Liraglutide: clinical pharmacology and considerations for therapy.
- Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.
- Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
- Use of Weight Loss Medications in Patients after Bariatric Surgery.
- Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
- Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
- GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.